ArticleJournal of maxillofacial and oral surgery2025
Efficacy of Combination of Intralesional Pentoxifylline and Dexamethasone with Intralesional Pentoxifylline, Intralesional Dexamethasone alone in the Treatment of Oral Submucous Fibrosis- A Pilot Study.
Article in Journal of maxillofacial and oral surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral submucous fibrosis (OSMF) is a debilitating oral disease, causing progressive loss of vascularity in the diseased mucosa, resulting in epithelial atrophy. Therefore, this pilot study aimed to use intralesional pentoxifylline to increase blood supply to the local tissues, helping in eliminating or reducing the severity of OSMF. Aims and Objectives: To comparatively evaluate the effectiveness of the combination of intralesional pentoxifylline and dexamethasone with pentoxifylline and dexamethasone alone in assessing the mouth opening, burning sensation, and USG parameters. The USG parameters included submucosal thickness, echoicity, and blood vascularity. The pilot study results were compared among the three study groups, in terms of increase in mouth opening, reduction in burning sensation, and the above-mentioned USG parameters. Methods: Patients were categorized randomly into Group I (n = 05), Group II (n = 05), and Group III (n = 05): Group I, intralesional dexamethasone 4 mg/ml, Group II, Intralesional PTX 1 mg/ml, while in Group III, combination of both drugs was administered, biweekly for 3 months along with active physiotherapy. Ultrasonography and colour Doppler were done pre- and post-treatment. Results: The increase in mouth opening in Group III was 115%, and in Group II that was 63.46% as compared to Group I 19.28% after 26th dose. The results of various parameters considered in this study were overall better in combination group as compared to other two groups. Conclusion: This regimen will improve quality of life, function, and patient compliance along with down staging of Grade of OSMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.